The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLRB | -95.19% | -99.14% | -61.37% | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +408% |
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | 23.8% |
| Market Cap | $17.88M | -79.4% |
| Market Cap / Employee | $1.63M | 0.0% |
| Employees | 11 | -52.2% |
| Net Income | -$4.44M | 69.7% |
| EBITDA | -$4.80M | 63.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.55M | -63.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.34M | -22.2% |
| Short Term Debt | $0.10M | 18.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.62% | 97.7% |
| Return On Invested Capital | -74.06% | -25.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.28M | 53.4% |
| Operating Free Cash Flow | -$4.28M | 53.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.00 | 1.88 | 1.41 | 1.82 | -96.75% |
| Price to Tangible Book Value | 234.85 | 31.64 | 1.41 | 1.82 | -99.64% |
| Enterprise Value to EBITDA | 0.56 | -0.47 | -0.46 | -1.56 | -68.38% |
| Return on Equity | -4693.4% | -208.7% | -273.9% | -145.4% | -69.36% |
| Total Debt | $0.49M | $0.47M | $0.45M | $0.43M | -15.76% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
